[1] |
Nathan H, Pawlik TM, Wolfgang CL, et al. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis[J]. J Gastrointest Surg, 2007, 11(11):1488-1496.
|
[2] |
Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J]. J Clin Oncol, 2013, 31(9):1188-1195.
|
[3] |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281.
|
[4] |
Hoffmann RT, Paprottka PM, Schön A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival[J]. Cardiovasc Intervent Radiol, 2012, 35(1):105-116.
|
[5] |
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9):603-605.
|
[6] |
Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007(8):16.
|
[7] |
Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study[J]. Cancer, 2008, 113(8):2119-2128.
|
[8] |
Saxena A, Bester L, Chua TC, et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option[J]. Ann Surg Oncol, 2010, 17(2):484-491.
|
[9] |
Mouli S, Memon K, Baker T, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis[J]. J Vasc Interv Radiol, 2013, 24(8):1227-1234.
|
[10] |
Rafi S, Piduru SM, El-Rayes B, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study[J]. Cardiovasc Intervent Radiol, 2013, 36(2):440-448.
|
[11] |
Mosconi C, Gramenzi A, Ascanio S, et al. Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study[J]. Br J Cancer, 2016, 115(3):297-302.
|
[12] |
Akinwande O, Shah V, Mills A, et al. Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity[J]. Hepat Oncol, 2017, 4(3):75-81.
|
[13] |
Jia Z, Paz-Fumagalli R, Frey G, et al. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results[J]. J Cancer Res Clin Oncol, 2017, 143(3):481-489.
|
[14] |
Swinburne NC, Biederman DM, Besa C, et al. Radioembolization for unresectable intrahepatic cholangiocarcinoma: review of safety, response evaluation criteria in solid tumors 1.1 imaging response and survival[J]. Cancer Biother Radiopharm, 2017, 32(5):161-168.
|
[15] |
Gangi A, Shah J, Hatfield N, et al. Intrahepatic cholangiocarcinoma treated with transarterial yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study[J]. J Vasc Interv Radiol, 2018, 29(8):1101-1108.
|
[16] |
Reimer P, Virarkar MK, Binnenhei M, et al. Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of yttrium-90 radioembolization: results in therapy-naïve patients[J]. Cardiovasc Intervent Radiol, 2018, 41(5):744-752.
|
[17] |
Koehler M, Rahbar K, Stegger L, et al. Selective internal radioembolization therapy with yttrium-90 resin microspheres in unresectable intrahepatic cholangiocarcinoma[J]. Cardiovasc Intervent Radiol, 2019, 42(3):S401.
|
[18] |
Köhler M, Harders F, Lohöfer F, et al. Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization[J]. J Clin Med, 2019, 9(1):56.
|
[19] |
Buettner S, Braat A, Margonis GA, et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis[J]. J Vasc Interv Radiol, 2020, 31(7):1035-1043, e1032.
|
[20] |
Bargellini I, Mosconi C, Pizzi G, et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study[J]. Cardiovasc Intervent Radiol, 2020, 43(9):1305-1314.
|
[21] |
Paprottka KJ, Galiè F, Ingrisch M, et al. Outcome and safety after 103 radioembolizations with yttrium-90 resin microspheres in 73 patients with unresectable intrahepatic cholangiocarcinoma-an evaluation of predictors[J]. Cancers, 2021, 13(21):5399.
|
[22] |
Sarwar A, Ali A, Ljuboja D, et al. Neoadjuvant yttrium-90 transarterial radioembolization with resin microspheres prescribed using the medical internal radiation dose model for intrahepatic cholangiocarcinoma[J]. J Vasc Interv Radiol, 2021, 32(11):1560-1568.
|
[23] |
Depalo T, Traino AC, Bargellini I, et al. Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres[J]. Sci Rep, 2021, 11(1):19745.
|
[24] |
Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success[J]. Int J Cancer, 2012, 131(3):733-740.
|
[25] |
Sinn M, Nicolaou A, Gebauer B, et al. Hepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase Ⅱ study[J]. Dig Dis Sci, 2013, 58(8):2399-2405.
|
[26] |
Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2020, 27(10): 3729-3737.
|
[27] |
Carvalho VO, Galastri FL, Affonso BB, et al. Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports[J]. Einstein, 2020(18):eRC4990.
|
[28] |
Benson AB, D'Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw, 2021, 19(5):541-565.
|
[29] |
Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23):2220-2229.
|
[30] |
Liu BJ, Gao S, Zhu X, et al. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma[J]. World J Gastrointest Oncol, 2020, 12(6):663-676.
|
[31] |
Yang C, Xia BR, Zhang ZC, et al. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant[J]. Front Immunol, 2020(11):577869.
|
[32] |
Chen WX, Li GX, Hu ZN, et al. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: a case report and literature review[J]. Medicine, 2019, 98(45):e17832.
|
[33] |
Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2020, 6(1):51-59.
|